Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Charles River Laboratories International, Inc. Common Stock (NY: CRL )

165.10 -2.86 (-1.70%)
Streaming Delayed Price Updated: 11:06 AM EST, Feb 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Charles River Laboratories International, Inc. Common Stock

< Previous 1 2 3 4 5 6 Next >
Uncover the latest developments among S&P500 stocks in today's session.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
Exploring the top movers within the S&P500 index during today's session.
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session. 
Via Chartmill
UFP Technologies (UFPT) Reports Q4: Everything You Need To Know Ahead Of Earnings
Medical products company UFP Technologies (NASDAQ:UFPT) will be announcing earnings results tomorrow morning. Here’s what to look for. 
Via StockStory
Analyst Sees Charles River As Preclinical Leader But Maintains Neutral Stance
Charles River's Q4 revenue topped estimates despite a 1.1% decline. The company forecasts a revenue drop in 2025, with biotech demand expected to stabilize. 
Via Benzinga
Earnings Scheduled For February 19, 2025
Via Benzinga
Analyst Expectations For Charles River's Future
Via Benzinga
What Analysts Are Saying About Charles River Stock
Via Benzinga
P/E Ratio Insights for Charles River
Via Benzinga
Which S&P500 stocks are moving on Wednesday?
Let's delve into the developments on the US markets one hour before the close of the markets on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session. 
Via Chartmill
In today's session, there are S&P500 stocks with remarkable trading volume.
Curious about which S&P500 stocks are generating unusual volume on Wednesday? Find out below. 
Via Chartmill
What's going on in today's session: S&P500 movers
Stay informed about the performance of the S&P500 index in the middle of the day on Wednesday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
Earnings To Watch: Repligen (RGEN) Reports Q4 Results Tomorrow
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be announcing earnings results tomorrow morning. Here’s what you need to know. 
Via StockStory
Evaluating Charles River: Insights From 12 Financial Analysts
Via Benzinga
The Analyst Verdict: Charles River In The Eyes Of 10 Experts
Via Benzinga
Charles River Laboratories (NYSE:CRL) Posts Better-Than-Expected Sales In Q4
Lab services company Charles River Laboratories (NYSE:CRL) reported Q4 CY2024 results exceeding the market’s revenue expectations, but sales fell by 1.1% year on year to $1.00 billion. Its non-GAAP... 
Via StockStory
Earnings To Watch: Charles River Laboratories (CRL) Reports Q4 Results Tomorrow
Lab services company Charles River Laboratories (NYSE:CRL) will be reporting earnings tomorrow before the bell. Here’s what investors should know. 
Via StockStory
Uncover the latest developments among S&P500 stocks in today's session.
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
Gapping S&P500 stocks in Monday's session
Let's have a look at the S&P500 gap up and gap down stocks in today's session. 
Via Chartmill
This STMicroelectronics Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday
Via Benzinga
This Spotify Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Via Benzinga
US Stocks Edge Higher As Traders Eye Inflation Data And Earnings Season Kickoff
Wall Street saw a modest uptick on Tuesday as investors turned their focus to upcoming US inflation data following a better-than-expected producer price index (PPI) report. 
Via Talk Markets
Topics Economy Stocks / Equities
Exposures Interest Rates
Charles River Q3 Earnings: CEO Notes Improved Biotech Funding And Stabilizing Demand - Here's Why
Charles River Labs Q3 revenue of $1.01 billion surpassed expectations; however, revenue declined 1.6% YoY, and operating margin dropped to 11.6% amid restructuring costs. 
Via Benzinga
S&P 500, Dow Hit Record Highs After Trump Win; Fear Index Drops 20%
Market surges to record highs after Trump's election, Republicans win Senate majority. Tech and small-caps up, VIX drops 22%. 
Via Benzinga
Topics Government Stocks
Exposures Political US Equities
This Ferguson Enterprises Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
This Alibaba Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga
This Netflix Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
Via Benzinga
Intel, Moderna And Dollar General Were Among Top 10 Large Cap Losers In August: Are The Others In Your Portfolio?
10 worst performing large-cap stocks in August: Super Micro, Dollar General, Snap, PDD Holdings, Intel, Tencent Music, Gold Fields, Charles River, Moderna, Neurocrine Biosciences. 
Via Benzinga
Magnificent 7 Miss Out, 2 Cybersecurity Stocks Stand Firm, Retailers Lag In Volatile August: Here Are The Top S&P 500 Gainers And Losers
The equity market was volatile in August, with the weakness seen early in the month dissipating amid a rise in rate-cut bets. 
Via Benzinga
Topics Stocks
Exposures US Equities
Warner Bros, Airbnb And Monster Beverage Are Among Top 10 Large Cap Losers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
These 10 stocks had the biggest drop last week, with McKesson Corporation, BIO-TECHNE Corp, and Warner Bros. Discovery, Inc. being the worst performers. 
Via Benzinga
EXCLUSIVE: Oragenics' Concussion Drug Clears FDA-Required Cardiotoxicity Testing, Planning For Phase Trials Underway
Oragenics announced its lead candidate, ONP-002, for treating concussion, which shows no cardiotoxicity in studies. Designed for nasal delivery to the brain, ONP-002 aims to address the significant... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.